Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease

References

• Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 2009; 27:Suppl 2 B71 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.04.070; PMID: 19477055
   PubMed Web of Science ®Google Scholar
• Bidmos FA, Neal KR, Oldfield NJ, Turner DP, Ala’Aldeen DA, Bayliss CD. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011; 49:506 - 12; http://dx.doi.org/10.1128/JCM.01322-10; PMID: 21123536
   PubMed Web of Science ®Google Scholar
• Jounio U, Saukkoriipi A, Bratcher HB, Bloigu A, Juvonen R, Silvennoinen-Kassinen S, et al. Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland. J Clin Microbiol 2012; 50:264 - 73; http://dx.doi.org/10.1128/JCM.05385-11; PMID: 22135261
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692 - 700; http://dx.doi.org/10.1016/j.vaccine.2006.03.034; PMID: 16621189
   PubMed Web of Science ®Google Scholar
• Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008:399-434.
   Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Neisseria meningitidis, 2009. Available via the Internet: http://www.cdc.gov/abcs/reports-findings/survreports/mening09.pdf. 2010.
   Google Scholar
• European Centre for Disease Prevention and Control. Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC. http://ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf 2011.
   Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:Suppl 2 B51 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.04.063; PMID: 19477562
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Boslego J. Immunologic Methods for Diagnosis of Infections by Gram-Negative Cocci. In: Rose NR, ed. Manual of clinical laboratory immunology. Washington, DC: ASM Press, 1997:473-83.
   Google Scholar
• Germinario C, Tafuri S, Napoli C, Montagna MT, Balducci MT, Fortunato F, et al. Young-adult carriers of Neisseria meningitidis in Puglia (Italy): will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines?. Hum Vaccin 2010; 6:1025 - 7; http://dx.doi.org/10.4161/hv.6.12.13145; PMID: 21150271
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004; 42:5146 - 53; http://dx.doi.org/10.1128/JCM.42.11.5146-5153.2004; PMID: 15528708
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853 - 61; http://dx.doi.org/10.1016/S1473-3099(10)70251-6; PMID: 21075057
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007; 31:101 - 7; http://dx.doi.org/10.1111/j.1574-6976.2006.00053.x; PMID: 17168998
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM, UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829 - 31; http://dx.doi.org/10.1016/S0140-6736(02)08679-8; PMID: 12044380
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365 - 6; http://dx.doi.org/10.1136/bmj.326.7385.365; PMID: 12586669
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840 - 7; http://dx.doi.org/10.1128/CVI.00529-09; PMID: 20219881
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Summary of notifiable diseases—United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:1 - 100; PMID: 21566560
   PubMedGoogle Scholar
• UK Health Protection Agency. Meningococcal Reference Unit: Isolates of Neisseria menengitidis; England and Wales, by serogroup & calendar year, 1998-2009. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1272032921946?pri 2010.
   Google Scholar
• Soriano-Gabarró M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011; 9:761 - 74; http://dx.doi.org/10.1586/eri.11.89; PMID: 21905785
   PubMed Web of Science ®Google Scholar
• Marsh JW, Shutt KA, Pajon R, Tulenko MM, Liu S, Hollick RA, et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine 2011; 29:6049 - 58; http://dx.doi.org/10.1016/j.vaccine.2011.06.025; PMID: 21704667
   PubMed Web of Science ®Google Scholar
• Núñez N, Martínez I, Izquierdo L, Álvarez N, López O. Portadores de Neisseria meningitidis y Neisseria lactamica en tres grupos de edades diferentes. VacciMonitor 2007; 16:1 - 6
   Google Scholar
• Parodi V, Allende F, Torres E, Macedo M, Maglione R, Algorta G. Portadores de Neisseria meningitidis en una poblaci6n de Montevideo. Rev Med Uruguay 1998; 14:221 - 5
   Google Scholar
• Ibarz-Pavón AB, Lemos AP, Gorla MC, Regueira M, Gabastou JM, SIREVA Working Group II. Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. PLoS One 2012; 7:e44102; http://dx.doi.org/10.1371/journal.pone.0044102; PMID: 22952888
   PubMed Web of Science ®Google Scholar
• Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004; 22:1087 - 96; http://dx.doi.org/10.1016/j.vaccine.2003.10.005; PMID: 15003635
   PubMed Web of Science ®Google Scholar
• Tondella ML, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, et al, The Active Bacterial Core Surveillance Team. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000; 38:3323 - 8; PMID: 10970378
   PubMed Web of Science ®Google Scholar
• Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines 2011; 10:617 - 34; http://dx.doi.org/10.1586/erv.11.50; PMID: 21604983
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379 - 89; http://dx.doi.org/10.1086/600141; PMID: 19534597
   PubMed Web of Science ®Google Scholar
• Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176:7566 - 75; PMID: 16751403
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501 - 10; PMID: 16785547
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010; 28:2122 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.12.027; PMID: 20044056
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088 - 100; http://dx.doi.org/10.1128/IAI.72.4.2088-2100.2004; PMID: 15039331
   PubMed Web of Science ®Google Scholar
• Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun 2005; 73:6838 - 45; http://dx.doi.org/10.1128/IAI.73.10.6838-6845.2005; PMID: 16177362
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010; 28:6086 - 93; http://dx.doi.org/10.1016/j.vaccine.2010.06.083; PMID: 20619376
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307 - 26; http://dx.doi.org/10.1084/jem.129.6.1307; PMID: 4977280
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006; 24:5093 - 107; http://dx.doi.org/10.1016/j.vaccine.2006.03.091; PMID: 16838413
   PubMed Web of Science ®Google Scholar
• Zlotnick G, Hoiseth SK, Jiang HQ, Murphy E, Andrew L, McNeil LK, et al. Epidemiology of the serogroup B Neisseria meningitidis (MnB) factor H binding protein in Strains Samples from Spain and Germany in the years 2001-2006 (poster P045). Presented at the 10th Meeting of the European Meningococcal Disease Society; Manchester, UK 2009.
   Google Scholar
• Ala’aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 2010; 28:7667 - 75; http://dx.doi.org/10.1016/j.vaccine.2010.09.038; PMID: 20875489
   PubMed Web of Science ®Google Scholar
• McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009; 27:3417 - 21; http://dx.doi.org/10.1016/j.vaccine.2009.01.075; PMID: 19200847
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, et al, 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597 - 607; http://dx.doi.org/10.1016/S1473-3099(12)70087-7; PMID: 22569484
   PubMed Web of Science ®Google Scholar
• Marshall H, Richmond P, Nissen M, Jiang Q, Anderson AS, Jansen KU, et al. A phase 1/2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults (poster P046). Presented at: 11th European Meningococcal Disease Society Congress, Ljubljana, Slovenia 2011.
   Google Scholar
• Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789 - 99; http://dx.doi.org/10.1084/jem.20021911; PMID: 12642606
   PubMed Web of Science ®Google Scholar